麻豆传媒

Promising results with an investigational CAR T-cell therapy in triple-negative breast cancer and non-small cell lung cancer (NSCLC) were tempered in a phase I trial, Lyell Immunopharma reported.

Merck acknowledged receiving a complete response letter from the FDA that described issues with a third-party manufacturing plant that precluded of patritumab deruxtecan for previously treated EGFR-mutated NSCLC.

Merck also of the small-molecule inhibitor xevinapant plus chemoradiotherapy for unresected locally advanced squamous cell carcinoma of the head and neck after an interim analysis showed the trial was unlikely to meet the primary endpoint.

AstraZeneca announced that neoadjuvant plus adjuvant durvalumab (Imfinzi) significantly improved event-free survival for in a phase III clinical trial.

But the company also said that a phase III trial of failed to meet the primary endpoint of disease-free survival.

A survey by the Environmental Working Group showed that only 17% of U.S. adults reported .

Ultrasound imaging may in Black women. (JAMA Oncology)

The FDA issued for increasing enrollment of underrepresented populations in clinical trials.

The agency also granted to epcoritamab (Epkinly) for relapsed/refractory follicular lymphoma.

And Shorla Oncology announced approval of a for breast and ovarian cancer.

Antibody-drug conjugate trastuzumab emtansine (Kadcyla) proved to be highly effective for preventing . (Journal of Clinical Oncology)

Standard use of intensity-modulated radiation therapy for led to significantly fewer cases of pneumonitis and other side effects as compared with 3D conformal radiotherapy. (JAMA Oncology)

Analysis of melanoma's improved prediction of whether the cancer would respond to immunotherapy. (Clinical Cancer Research)

Comment